SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
DMAC

DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$8.25+$0.23 (+2.87%)
 
Market cap
$445M
Insider Score
Health Score
Analyst consensus
Listed since
Aug 3, 2012
Market Cap$445.15M+8.1%
Revenue (ttm)$0
Net Income-$40.23M-26.0%
EPS-$0.76-7.0%
Shares Out53.96M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume313,537
Open$8.12
Previous Close$8.02
Day's Range$7.91 - $8.37
52-Week Range$5.25 - $11.00
Beta0.94
AnalystsBuy
Price Target$8.33(+0.97%)
Earnings DateMar 29, 2027

About DMAC

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

Address
Two Carlson Parkway, Minneapolis, MN, 55305, US
Market Cap
445 million
Employees
35
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$7.63M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From DMAC’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
+2.87%
5 Days
-4.62%
1 Month
-5.06%
6 Months
+42.98%
1 Year
+8.13%

$DMAC stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in DMAC holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by DMAC's directors and management

Net Shares Purchased by Insiders−2M−1M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

DMAC Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New DMAC patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to DMAC from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in DMAC

IWMiShares Russell 2000 ETF$7.55M
VXFVanguard Extended Market ETF$3.34M
IWOiShares Russell 2000 Growth ETF$2.80M
VTWOVanguard Russell 2000 ETF$1.99M
IWCiShares Micro-Cap ETF$893.47K
VTWGVanguard Russell 2000 Growth ETF$375.62K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from DMAC’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
70

News check: Q3 2026 earnings coverage focused on REMEDI 2 interim analysis update, suggesting progress on key pipeline program with positive clinical developments.

Recent Insider Activity

Buys
7
Sells
0
Buy Value
$7.63M
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IWCiShares Micro-Cap ETF0.09%

Weight is the stock’s share of each fund’s holdings.